Back to top

Image: Bigstock

Laboratory Corporation of America Holdings

Read MoreHide Full Article

LabCorp’s first operational quarter post the acquisition of Covance highly impresses us with beats over the Zacks Consensus Estimate on both lines. According to the company, this quarter highlighted solid organic revenue growth and operating leverage. We believe that, with the integration of Covance, LabCorp is perfectly positioned to drive long-term profitability through a combination of advanced diagnostics, drug development expertise, and knowledge services. Besides, Project LaunchPad is expected to garner net savings in excess of $150 million over the next three years ($50 million in 2015). However, the current economic uncertainty including challenging volume environment for testing laboratories and utilization weaknesses are looming headwinds.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Laboratory Corporation of America Holdings (LH) - free report >>

Published in